Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ERJP | ISIN: US00688A2050 | Ticker-Symbol:
NASDAQ
06.06.25 | 17:17
0,550 US-Dollar
-16,25 % -0,107
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ADIAL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ADIAL PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ADIAL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:35ADIAL PHARMACEUTICALS, INC. - S-1, General form for registration of securities3
30.05.Adial Pharmaceuticals files to register resale of 6.7M shares from warrant conversions2
30.05.ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report1
15.05.Adial Pharmaceuticals reports Q1 results1
15.05.Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update204GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies...
► Artikel lesen
ADIAL PHARMACEUTICALS Aktie jetzt für 0€ handeln
15.05.ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report1
14.05.ADIAL PHARMACEUTICALS, INC. - 10-Q, Quarterly Report2
13.05.Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study112Glen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies...
► Artikel lesen
08.05.FDA to Review Adial's Phase 3 Trial Plan for AUD Treatment2
08.05.EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program1
02.05.Adial Pharmaceuticals sichert sich 2,75 Millionen US-Dollar durch Optionsscheinausübung1
02.05.Adial Pharmaceuticals secures $2.75 million through warrant exercise1
02.05.Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds1
01.05.ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report1
01.05.Adial Pharmaceuticals secures patent for addiction treatment2
01.05.Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders2
01.05.EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders2
21.03.ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report1
05.03.Adial Pharmaceuticals reports FY results4
04.03.Rodman & Renshaw maintains Adial stock Buy rating, $8 target5
Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1